-

Applied DNA to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that Dr. James A. Hayward, president and CEO, will participate in a fireside chat at the virtual H.C. Wainwright BIOCONNECT 2021 Conference to be held January 11-14, 2021. The fireside chat will be hosted by Yi Chen, Managing Director, H.C. Wainwright Equity Research, and Applied DNA covering analyst.

The fireside chat will be available for on-demand listening beginning on Monday, January 11, 2021, at 6:00 a.m. Eastern Standard Time on the IR Calendar section of the Applied DNA website at www.adnas.com. An archived replay of the fireside chat will be available on the Company’s website for 90 days.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN’, and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW’.

Applied DNA is a member of the Russell Microcap® Index.

Contacts

Investor contact: Sanjay M. Hurry, Applied DNA Sciences, 917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN

Industry:

Applied DNA Sciences, Inc.

NASDAQ:APDN
Details
Headquarters: Stony Brook, New York
Website: www.adnas.com
CEO: James Hayward
Employees: 69
Organization: PUB
Revenues: $18,168,677 (2022)
Net Income: $(8,270,059) (2022)
Release Versions
English
$Cashtags
$APDN
Hashtags
#COVID19
#COVID19diagnostics
#biotech
#coronavirus
#moleculardiagnostictest
#surveillancetesting

Contacts

Investor contact: Sanjay M. Hurry, Applied DNA Sciences, 917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN

More News From Applied DNA Sciences, Inc.

Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET. Date & Time: Thursday, May 11 @ 4:30 p.m....

Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal Regulation

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, announced that its CertainT® supply chain traceability platform is featured in an article on the home page of the New York Times website today. The article, titled "How A.I. and DNA Are Unlocking the Mysteries of Global Supply Chains," centers on the mounting need for the textile and other industries to employ tracing technologies to ensure compliance with the U...

Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks. The quantity was produced by the Company’s LinearDNA™ platform under a large recurring purchase order with a global manufacturer of in vitro diagnostics that was announced in the first quart...
Back to Newsroom